DZ3442A1 - Combinaison de fenofibrate et de coenzyme q10 pour le traitement de dysfonctionnement endothelial - Google Patents

Combinaison de fenofibrate et de coenzyme q10 pour le traitement de dysfonctionnement endothelial

Info

Publication number: DZ3442A1
Authority: DZ; Algeria
Prior art keywords: fenofibrate; coenzyme; treatment; combination; endothelial dysfunction
Prior art date: 2000-10-26

Application number

DZ013442A

Other languages

English (en)

Inventor

Gerald Watts

David Playford

Original Assignee

Fournier Lab Ireland Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-26

Filing date

2001-10-23

Publication date

2002-05-02

2000-10-26 Priority claimed from AUPR1038A external-priority patent/AUPR103800A0/en

2001-02-28 Priority claimed from AUPR3424A external-priority patent/AUPR342401A0/en

2001-10-23 Application filed by Fournier Lab Ireland Ltd filed Critical Fournier Lab Ireland Ltd

2002-05-02 Application granted granted Critical

2002-05-02 Publication of DZ3442A1 publication Critical patent/DZ3442A1/fr

Links

206010048554 Endothelial dysfunction Diseases 0.000 title 1
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title 1
230000008694 endothelial dysfunction Effects 0.000 title 1
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 title 1
229960002297 fenofibrate Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Toxicology (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DZ013442A 2000-10-26 2001-10-23 Combinaison de fenofibrate et de coenzyme q10 pour le traitement de dysfonctionnement endothelial DZ3442A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
AUPR1038A AUPR103800A0 (en)	2000-10-26	2000-10-26	Compositions for the treatment of endothelial dysfunction
AUPR3424A AUPR342401A0 (en)	2001-02-28	2001-02-28	Compositions for the treatment of endothelial dysfunction
PCT/EP2001/012425 WO2002034259A1 (fr)	2000-10-26	2001-10-23	Combinaison de fenofibrate et de coenzyme q10 permettant de traiter un dysfonctionnement endothelial

Publications (1)

Publication Number	Publication Date
DZ3442A1 true DZ3442A1 (fr)	2002-05-02

Family

ID=25646491

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ013442A DZ3442A1 (fr)	2000-10-26	2001-10-23	Combinaison de fenofibrate et de coenzyme q10 pour le traitement de dysfonctionnement endothelial

Country Status (29)

Country	Link
US (1)	US7410983B2 (fr)
EP (1)	EP1328266B1 (fr)
JP (1)	JP4236464B2 (fr)
KR (1)	KR100862129B1 (fr)
CN (1)	CN1220488C (fr)
AR (1)	AR035071A1 (fr)
AT (1)	ATE316787T1 (fr)
AU (1)	AU2176502A (fr)
BG (1)	BG65979B1 (fr)
BR (1)	BR0114701A (fr)
CA (1)	CA2426625C (fr)
CY (1)	CY1105007T1 (fr)
CZ (1)	CZ301282B6 (fr)
DE (1)	DE60117046T2 (fr)
DK (1)	DK1328266T3 (fr)
DZ (1)	DZ3442A1 (fr)
EE (1)	EE05281B1 (fr)
ES (1)	ES2257457T3 (fr)
HU (1)	HUP0303566A3 (fr)
IL (2)	IL155524A0 (fr)
MA (1)	MA25847A1 (fr)
MX (1)	MXPA03003733A (fr)
NO (1)	NO332260B1 (fr)
PL (1)	PL212952B1 (fr)
PT (1)	PT1328266E (fr)
RU (1)	RU2003111175A (fr)
SK (1)	SK287992B6 (fr)
TN (1)	TNSN01151A1 (fr)
WO (1)	WO2002034259A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003005999A2 (fr)	2001-07-11	2003-01-23	Boehringer Ingelheim Pharmaceuticals, Inc.	Methodes permettant de traiter des maladies induites par les cytokines
CA2481371A1 (fr) *	2002-03-11	2003-09-18	Peter Zahradka	Utilisation d'agonistes de ppar alpha dans le traitement de maladies vasculaires et renales
US20070225614A1 (en) *	2004-05-26	2007-09-27	Endothelix, Inc.	Method and apparatus for determining vascular health conditions
FR2845602B1 (fr) *	2002-10-11	2005-07-08	Servier Lab	Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
GB0309154D0 (en) *	2003-01-14	2003-05-28	Aventis Pharma Inc	Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
JP2005104951A (ja) *	2003-01-17	2005-04-21	Kirin Brewery Co Ltd	血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品
FR2868313B1 (fr) *	2004-03-31	2008-08-15	Servier Lab	Nouvelle association entre un compose heterocyclique et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
EP1621200A1 (fr) *	2004-07-26	2006-02-01	Fournier Laboratories Ireland Limited	Combinaison pharmaceutique comprenant un inhibiteur de l'aggregation des thrombocytes et un fibrate
ES2619303T3 (es)	2005-06-01	2017-06-26	Edison Pharmaceuticals, Inc.	Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
SI1933821T1 (sl)	2005-09-15	2020-11-30	Ptc Therapeutics, Inc.	Repne variante redoks-aktivnih terapevtikov za zdravljenje mitohondrijskih bolezni in drugih bolezni ter modulacijo energijskih biooznačevalcev
EP1785133A1 (fr) *	2005-11-10	2007-05-16	Laboratoires Fournier S.A.	Utilisation du fenofibrate ou d'un de ses dérivés pour la prevention de la retinopathie diabetique
WO2007100652A2 (fr)	2006-02-22	2007-09-07	Edison Pharmaceuticals, Inc.	Variants à chaînes latérales d'agents thérapeutiques ayant une activité oxydoréductrice pour le traitement de maladies mitochondriales et d'autres conditions et pour la modulation de biomarqueurs énergétiques
US7897326B2 (en)	2006-03-16	2011-03-01	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Peroxisome-proliferator activated receptor-alpha agonists for organ preservation
US20070225606A1 (en) *	2006-03-22	2007-09-27	Endothelix, Inc.	Method and apparatus for comprehensive assessment of vascular health
US20080027330A1 (en) *	2006-05-15	2008-01-31	Endothelix, Inc.	Risk assessment method for acute cardiovascular events
US20080081963A1 (en) *	2006-09-29	2008-04-03	Endothelix, Inc.	Methods and Apparatus for Profiling Cardiovascular Vulnerability to Mental Stress
KR100989093B1 (ko)	2008-01-18	2010-10-25	한화제약주식회사	생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물
MX363223B (es)	2008-09-10	2019-03-15	Bioelectron Tech Corp	Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
WO2010088378A1 (fr) *	2009-01-29	2010-08-05	Levine Joshua D	Procédé d'ajout d'agents botaniques/de suppléments de régime à des agents pharmaceutiques dans un régime pharmacothérapeutique
US8973851B2 (en)	2009-07-01	2015-03-10	The Procter & Gamble Company	Apparatus and methods for producing charged fluid droplets
EP2551255B1 (fr) *	2010-03-26	2017-11-08	Vivacell Biotechnology España, S.L	Dérivés quinone de cannabinoïdes
RU2554500C2 (ru) *	2013-09-20	2015-06-27	Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ)	Способ лечения ишемического инсульта
US10703701B2 (en)	2015-12-17	2020-07-07	Ptc Therapeutics, Inc.	Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
WO2019084540A1 (fr)	2017-10-27	2019-05-02	Zeta Biolongevity, Inc.	Compositions et méthodes pour traiter et prévenir la protéinurie et l'érosion endothéliale
CN110907407B (zh) *	2019-12-03	2022-02-25	东北石油大学	一种基于spr的高灵敏度光子准晶体光纤折射率传感器

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5229385A (en)	1986-01-30	1993-07-20	Takeda Chemical Industries, Ltd.	Quinone derivatives, their production and use
FR2627696B1 (fr)	1988-02-26	1991-09-13	Fournier Innovation Synergie	Nouvelle forme galenique du fenofibrate
FI102273B (fi)	1989-09-11	1998-11-13	Eisai Co Ltd	Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyt tö
FR2730231B1 (fr)	1995-02-02	1997-04-04	Fournier Sca Lab	Association de fenofibrate et de vitamine e, utilisation en therapeutique
US6063407A (en) *	1995-02-16	2000-05-16	The General Hospital Corporation	Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
WO1997028149A1 (fr) *	1996-02-02	1997-08-07	Merck & Co., Inc.	Procede pour augmenter les niveaux de cholesterol hdl
GB9606805D0 (en)	1996-03-30	1996-06-05	Glaxo Wellcome Inc	Medicaments
HUP0400931A2 (hu)	1997-11-28	2004-07-28	Karsanov, Nyikolai Vaszilievics	Hypoxia és ischaemia elleni gyógyszer
WO2001015593A2 (fr) *	1999-09-02	2001-03-08	Drake Larson	Compositions de reduction de formation de la plaque vasculaire et procedes d'utilisation associes

2001
- 2001-10-23 WO PCT/EP2001/012425 patent/WO2002034259A1/fr not_active Ceased
- 2001-10-23 EE EEP200300165A patent/EE05281B1/xx not_active IP Right Cessation
- 2001-10-23 CN CNB01817972XA patent/CN1220488C/zh not_active Expired - Fee Related
- 2001-10-23 DZ DZ013442A patent/DZ3442A1/fr active
- 2001-10-23 CA CA2426625A patent/CA2426625C/fr not_active Expired - Fee Related
- 2001-10-23 HU HU0303566A patent/HUP0303566A3/hu unknown
- 2001-10-23 US US10/399,639 patent/US7410983B2/en not_active Expired - Fee Related
- 2001-10-23 SK SK508-2003A patent/SK287992B6/sk unknown
- 2001-10-23 JP JP2002537311A patent/JP4236464B2/ja not_active Expired - Fee Related
- 2001-10-23 KR KR1020037004793A patent/KR100862129B1/ko not_active Expired - Fee Related
- 2001-10-23 ES ES01988586T patent/ES2257457T3/es not_active Expired - Lifetime
- 2001-10-23 AT AT01988586T patent/ATE316787T1/de active
- 2001-10-23 DK DK01988586T patent/DK1328266T3/da active
- 2001-10-23 PT PT01988586T patent/PT1328266E/pt unknown
- 2001-10-23 BR BR0114701-3A patent/BR0114701A/pt not_active Application Discontinuation
- 2001-10-23 CZ CZ20031148A patent/CZ301282B6/cs not_active IP Right Cessation
- 2001-10-23 DE DE60117046T patent/DE60117046T2/de not_active Expired - Lifetime
- 2001-10-23 PL PL361635A patent/PL212952B1/pl not_active IP Right Cessation
- 2001-10-23 IL IL15552401A patent/IL155524A0/xx active IP Right Grant
- 2001-10-23 AU AU2176502A patent/AU2176502A/xx active Pending
- 2001-10-23 RU RU2003111175/15A patent/RU2003111175A/ru not_active Application Discontinuation
- 2001-10-23 MX MXPA03003733A patent/MXPA03003733A/es active IP Right Grant
- 2001-10-23 EP EP01988586A patent/EP1328266B1/fr not_active Expired - Lifetime
- 2001-10-25 TN TNTNSN01151A patent/TNSN01151A1/en unknown
- 2001-10-26 AR ARP010105032A patent/AR035071A1/es unknown
2003
- 2003-04-21 IL IL155524A patent/IL155524A/en not_active IP Right Cessation
- 2003-04-24 NO NO20031851A patent/NO332260B1/no not_active IP Right Cessation
- 2003-04-25 MA MA27124A patent/MA25847A1/fr unknown
- 2003-04-25 BG BG107765A patent/BG65979B1/bg unknown
2006
- 2006-03-21 CY CY20061100400T patent/CY1105007T1/el unknown

Also Published As

Publication number	Publication date
HUP0303566A3 (en)	2005-05-30
JP4236464B2 (ja)	2009-03-11
EP1328266A1 (fr)	2003-07-23
BR0114701A (pt)	2003-11-18
MXPA03003733A (es)	2004-10-15
EE05281B1 (et)	2010-04-15
US20040022778A1 (en)	2004-02-05
DE60117046D1 (de)	2006-04-13
HK1057340A1 (en)	2004-04-02
KR100862129B1 (ko)	2008-10-09
EP1328266B1 (fr)	2006-02-01
PL361635A1 (en)	2004-10-04
KR20030055276A (ko)	2003-07-02
IL155524A0 (en)	2003-11-23
MA25847A1 (fr)	2003-07-01
JP2004512302A (ja)	2004-04-22
CY1105007T1 (el)	2009-11-04
DE60117046T2 (de)	2006-09-28
ES2257457T3 (es)	2006-08-01
IL155524A (en)	2008-08-07
RU2003111175A (ru)	2004-09-10
SK287992B6 (sk)	2012-09-03
WO2002034259A1 (fr)	2002-05-02
PT1328266E (pt)	2006-05-31
NO20031851L (no)	2003-06-24
NO332260B1 (no)	2012-08-13
CA2426625C (fr)	2010-06-01
BG65979B1 (bg)	2010-08-31
AU2176502A (en)	2002-05-06
ATE316787T1 (de)	2006-02-15
DK1328266T3 (da)	2006-06-06
EE200300165A (et)	2003-06-16
AR035071A1 (es)	2004-04-14
CA2426625A1 (fr)	2002-05-02
CN1471390A (zh)	2004-01-28
SK5082003A3 (en)	2003-11-04
US7410983B2 (en)	2008-08-12
CN1220488C (zh)	2005-09-28
HUP0303566A2 (hu)	2004-03-01
PL212952B1 (pl)	2012-12-31
NO20031851D0 (no)	2003-04-24
TNSN01151A1 (en)	2005-11-10
CZ301282B6 (cs)	2009-12-30
BG107765A (bg)	2004-02-27

Publication	Publication Date	Title
DZ3442A1 (fr)	2002-05-02	Combinaison de fenofibrate et de coenzyme q10 pour le traitement de dysfonctionnement endothelial
MA25823A1 (fr)	2003-07-01	Compositions pour le traitement de l'eau.
FR12C0077I2 (fr)	2013-08-16	Composition pour le traitement des condylomes génitaux
IL155092A0 (en)	2003-10-31	Compounds useful in the treatment of inflammatory diseases
AR027945A1 (es)	2003-04-16	Uso de pramipexol en el tratamiento de transtornos de adiccion
DK1176964T3 (da)	2007-01-15	Brug af ET743 til behandling af cancer
ITMI20001705A0 (it)	2000-07-25	Procedimento per la denitrificazione delle acque
DK1345598T3 (da)	2008-02-04	Anvendelsen af rosiglitazon til behandling af psykiatriske lidelser
DZ3014A1 (fr)	2004-03-27	Médicaments pour le traitement de l'hypertension.
FR2812197B1 (fr)	2003-01-03	Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
EE200200590A (et)	2004-04-15	Bradükardiaalsete toimeainete kasutamine hüpertroofiaga seotud müokardiaalsete haiguste ravimiseks ja uudsed ravimikombinatsioonid
EP1286721A4 (fr)	2006-12-06	Catheter biliaire orientable
EP1359885A4 (fr)	2005-03-16	Inhibiteurs de nos pour le traitement des rides
NO20031525D0 (no)	2003-04-03	Kjemokinmutanter i behandlingen av multippel sklerose
NO20030978L (no)	2003-04-16	Behandling av urindysfunksjon
EP1161255A4 (fr)	2002-07-17	Procedes et compositions pour le traitement de la dyserection
MA25852A1 (fr)	2003-07-01	Methode pour le traitement de l'inflammation.
PT1152756E (pt)	2005-09-30	Derivados de anticonvulsivo uteis no tratamento do autismo
EP1572129A4 (fr)	2007-03-28	Derives d'amidine pour le traitement des amyloses
DK1257278T3 (da)	2006-06-12	Anvendelse af mirtazapin til behandling af sövnforstyrrelser
EP1172113A4 (fr)	2004-06-30	Remedes pour le traitement des neuropathies automatiques
FR2808687B1 (fr)	2003-12-05	Medicament contenant des substances polysaccharidiques pour l'activation de l'apoptose
FR2805983B3 (fr)	2002-02-01	Douche
PT1273556E (pt)	2006-08-31	Estacao de tratamento simbiotico de aguas residuais.
GB0007217D0 (en)	2000-05-17	Materials and methods relating to the treatment of leukaemias